RxDoctor Payments Data

Kevin Guevarra, DO

Family Medicine · Olathe, KSNPI 1356744981

Payments from drug & device makers

$908in general payments, 2019–2025

Across 56 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$217
  • Lilly USA, LLC$189
  • Pfizer$181
  • GSK$128
  • AbbVie$77
  • Otsuka America Pharmaceutical, Inc.$58
  • plus $58 from 3 others

What the payments were for

  • Food & beverage$908100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk12$217
Lilly USA, LLC12$189
Pfizer17$181
GSK3$128
AbbVie(2 entities)5$77
Otsuka America Pharmaceutical, Inc.3$58
Amgen2$32
AstraZeneca1$14
Johnson & Johnson1$11

How this compares

$908 in reported general payments places this provider in the 60th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$48,238
Medicare patients
224
Services billed
17,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$47,073
TrulicityDulaglutide26$39,940
MounjaroTirzepatide28$38,159
OzempicSemaglutide15$31,620
JardianceEmpagliflozin28$23,639
JanuviaSitagliptin Phosphate14$20,166
JanumetSitagliptin Phos/Metformin Hcl12$10,146
LinzessLinaclotide15$8,628
NorliqvaAmlodipine Besylate14$7,682
Spiriva RespimatTiotropium Bromide12$6,018
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$4,488
Atorvastatin Calcium386$3,529
Pantoprazole Sodium207$3,152
Albuterol Sulfate HfaAlbuterol Sulfate85$2,810
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$2,726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$189$78,09854 claims
PfizerEliquis$181$47,07338 claims
Novo NordiskOzempic$217$31,62015 claims
AbbVieLinzess$77$8,62815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Olathe

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →